翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

未开盘 04-23 16:09:13

16.340

+0.300

+1.87%

最高16.580	最低15.940	成交量486.89万
今开16.000	昨收16.040	日振幅3.99%
总市值969.51亿	流通市值969.51亿	总股本59.33亿
成交额7,930万	换手率0.08%	流通股本59.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":16.34,"timestamp":1713859753015,"preClose":16.04,"halted":0,"volume":4868920,"delay":0,"floatShares":5933350070,"shares":5933350070,"eps":0.59700716,"marketStatus":"未开盘","marketStatusCode":0,"change":0.3,"latestTime":"04-23 16:09:13","open":16,"high":16.58,"low":15.94,"amount":79299953,"amplitude":0.0399,"askPrice":16.34,"askSize":140000,"bidPrice":16.3,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":0.563987815029853,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713922200000},"adr":0,"listingDate":1560441600000,"adjPreClose":16.04,"dividendRate":0.012779,"openAndCloseTimeList":[[1713835800000,1713844800000],[1713848400000,1713859200000]],"volumeRatio":0.919335,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692?invite=TIGER026","defaultTab":"news","newsList":[{"id":"2429300071","title":"翰森制药(03692)出现大手买入36.2万股，成交价$16.28，涉资589.336万","url":"https://stock-news.laohu8.com/highlight/detail?id=2429300071","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429300071?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:30","pubTimestamp":1713850200,"startTime":"0","endTime":"0","summary":"[大手成交]翰森制药(03692)在下午01:30出现大手买入，成交量为36.2万，成交价为港币$16.28，涉资589.336万。至目前为止，股价升1.496%，今日最高价为$16.3，而最低价为$15.94，总成交量为233.221万股，总成交金额港币$3.77千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2404233037/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2429499276","title":"翰森制药盘中异动 下午盘股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429499276","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429499276?lang=zh_cn&edition=full","pubTime":"2024-04-22 14:02","pubTimestamp":1713765777,"startTime":"0","endTime":"0","summary":"2024年04月22日下午盘14时02分，翰森制药股票出现波动，股价急速拉升5.06%。截至发稿，该股报16.160港元/股，成交量305.242万股，换手率0.05%，振幅5.07%。翰森制药股票所在的药品行业中，整体涨幅为0.34%。其相关个股中，开拓药业-B、泰凌医药、中国生物制药涨幅较大，振幅较大的相关个股有开拓药业-B、精优药业、泰凌医药，振幅分别为17.24%、10.71%、9.52%。翰森制药公司简介：翰森制药集团有限公司是一家主要从事药品研发、生产及销售业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221402577a54688a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221402577a54688a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428763566","title":"翰森制药(03692)根据受限制股份单位的计划发行230万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2428763566","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428763566?lang=zh_cn&edition=full","pubTime":"2024-04-19 17:20","pubTimestamp":1713518415,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2024年4月19日根据公司于2019年5月27日批准及采纳的受限制股份单位的计划发行230万股公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1105424.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428571036","title":"南向资金4月18日净卖出翰森制药100.80万股 连续7日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428571036","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428571036?lang=zh_cn&edition=full","pubTime":"2024-04-19 09:31","pubTimestamp":1713490290,"startTime":"0","endTime":"0","summary":"4月18日，南向资金减持翰森制药100.80万股连续7日减持。截止当日收盘，港股通共持有翰森制药17852.43万股，占流通股3.00%。翰森制药近5个交易日下跌3.21%，港股通累计减持272.80万股；近20个交易日上涨3.30%，港股通累计增持863.52万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190943348b384b21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190943348b384b21&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427869500","title":"翰森制药盘中异动 快速跳水5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427869500","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427869500?lang=zh_cn&edition=full","pubTime":"2024-04-16 10:13","pubTimestamp":1713233583,"startTime":"0","endTime":"0","summary":"2024年04月16日早盘10时13分，翰森制药股票出现波动，股价快速跳水5.06%。截至发稿，该股报15.381港元/股，成交量148.032万股，换手率0.02%，振幅4.07%。机构评级方面，在所有19家参与评级的机构中，84%的券商给予买入建议，11%的券商给予持有建议，5%的券商给予卖出建议。翰森制药股票所在的药品行业中，整体跌幅为0.18%。翰森制药公司简介：翰森制药集团有限公司是一家主要从事药品研发、生产及销售业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161013037920c537&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161013037920c537&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427026342","title":"翰森制药04月15日主力资金流入174万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2427026342","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427026342?lang=zh_cn&edition=full","pubTime":"2024-04-15 16:15","pubTimestamp":1713168957,"startTime":"0","endTime":"0","summary":"04月15日, 翰森制药股价涨0.87%，报收16.20元，成交金额4239万元，换手率0.04%，振幅2.24%，量比0.63。翰森制药今日主力资金净流入174万元，连续3日净流入，上一交易日主力净流入244万元，今日环比减少28.69%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为56.25%，平均涨幅为2.31%。该股近5个交易日上涨5.45%，主力资金累计净流入311万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1667万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415161628877e8e45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415161628877e8e45&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426236694","title":"翰森制药终于兑现了承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2426236694","media":"中金在线","top":-1,"share":"https://www.laohu8.com/m/news/2426236694?lang=zh_cn&edition=full","pubTime":"2024-04-11 17:19","pubTimestamp":1712827144,"startTime":"0","endTime":"0","summary":"2023年年报披露，翰森制药去年实现营业收入101.4亿元，比起5年前看似提升不大，但这钱里三分之二都是创新药收入，早就今非昔比了。阿美替尼是支撑翰森创新药营收的绝对主力。2023年，翰森制药第7款创新药培莫沙肽注射液上市，目前这7款上市创新药都列入了国家医保目录。从2019年上市到如今，翰森制药目前是港股医药企业中市值排名前三位的，和百济神州、药明康德站在一起。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404111721018b0f7bf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404111721018b0f7bf7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425536316","title":"翰森制药04月05日获主力加仓229万元 环比增加536.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425536316","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425536316?lang=zh_cn&edition=full","pubTime":"2024-04-05 16:16","pubTimestamp":1712304971,"startTime":"0","endTime":"0","summary":"04月05日, 翰森制药股价涨1.54%，报收15.86元，成交金额5654万元，换手率0.06%，振幅4.99%，量比0.62。翰森制药今日主力资金净流入229万元，连续3日净流入，上一交易日主力净流入36万元，今日环比增加536.11%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为60.00%，平均涨幅为2.31%。该股近5个交易日上涨6.59%，主力资金累计净流入1137万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2310万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040516163487e124bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040516163487e124bf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424316068","title":"翰森制药(03692.HK)新药“HS-10504片”临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2424316068","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2424316068?lang=zh_cn&edition=full","pubTime":"2024-04-04 23:21","pubTimestamp":1712244060,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，附属江苏豪森及上海翰森自主研发的1类新药“HS-10504片”已获中国国家药品监督管理局核准签发的临床试验通知书，拟用于治疗晚期非小细胞肺癌，具体适应症待临床试验后确定。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-03 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1340091/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2424818249","title":"翰森制药(03692.HK)：HS-10504片获临床试验通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2424818249","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2424818249?lang=zh_cn&edition=full","pubTime":"2024-04-03 18:35","pubTimestamp":1712140504,"startTime":"0","endTime":"0","summary":"格隆汇4月3日丨翰森制药(03692.HK)公告，由公司附属公司江苏豪森药业集团有限公司及上海翰森生物医药科技有限公司自主研发的1类新药HS-10504片已获得中国国家药品监督管理局核准签发的临床试验通知书，拟用于治疗晚期非小细胞肺癌，具体适应症待临床试验后确定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031835128aed1d73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031835128aed1d73&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424549890","title":"翰森制药(03692)：“HS-10504片”拟用于治疗晚期非小细胞肺癌获临床试验通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2424549890","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2424549890?lang=zh_cn&edition=full","pubTime":"2024-04-03 18:34","pubTimestamp":1712140471,"startTime":"0","endTime":"0","summary":"翰森制药(03692)公布，由公司附属公司江苏豪森药业集团有限公司及上海翰森生物医...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_1.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_1.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1098528.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424183461","title":"《大行报告》汇丰研究微升翰森制药(03692.HK)目标价至18.6元  创新平台领先足迹遍布全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2424183461","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2424183461?lang=zh_cn&edition=full","pubTime":"2024-04-03 10:33","pubTimestamp":1712111580,"startTime":"0","endTime":"0","summary":"汇丰研究发表研究报告指，在行业反贪腐监管的影响下，翰森制药2023年收入按年增长7.7%，其中去年下半年收入增长13%，纯利增长55%，超出该行预期，相信主要来自创新药及业务拓展的增长所推动。汇丰研究强调，翰森制药推有发展良好的创新平台、全球布局及稳健增长前景，维持“买入”评级，目标价上调至18.6元。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201021164017612_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201021164017612_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1339851/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2423347107","title":"翰森制药集团全球研发总部在上海开工建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2423347107","media":"21世纪经济报道","top":-1,"share":"https://www.laohu8.com/m/news/2423347107?lang=zh_cn&edition=full","pubTime":"2024-03-29 11:31","pubTimestamp":1711683060,"startTime":"0","endTime":"0","summary":"南方财经3月29日电，记者获悉，翰森制药集团全球研发总部今日在上海开工培土奠基。该全球研发总部项目总建筑面积约9万平方米，涵盖生物实验室与中试单元、化学研发实验室、研发办公室及综合服务楼等配套设施。项目将建成全球领先的抗体偶联技术、人工智能技术、蛋白降解靶向嵌合体(PROTAC)技术、多肽药物技术等创新药研发技术平台，并承担全球研发管理职能。（21世纪经济报道）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403291131278b7056a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403291131278b7056a2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422162946","title":"翰森制药(3692.HK)：创新药将引领收入稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2422162946","media":"中泰国际","top":-1,"share":"https://www.laohu8.com/m/news/2422162946?lang=zh_cn&edition=full","pubTime":"2024-03-28 19:41","pubTimestamp":1711626118,"startTime":"0","endTime":"0","summary":"医药产品中，创新药收入同比增加37.1%至68.7 亿元，占公司总收入的比例从2022 年的53.4%上升至67.9%。公司管理层表示肿瘤药领域主要创新药阿美乐医保谈判降价后销量快速增加，2023 年销售收入同比增加近两成。阿美乐2024 年以来销量仍保持强劲增长，管理层预计2024 年仍将获得20%左右收入增长。公司管理层表示按照目前的临床试验进度，阿美乐用于肺癌的术后辅助治疗及联合化疗使用的新适应症有望于2025 年获批，因此阿美乐将引领肿瘤药业务收入稳健增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032819420287c08411&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032819420287c08411&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422156410","title":"花旗：维持翰森制药(03692)“买入”评级 目标价上调至28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422156410","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422156410?lang=zh_cn&edition=full","pubTime":"2024-03-28 16:54","pubTimestamp":1711616074,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研究报告称，维持翰森制药(03692)“买入”评级，将公司今年和明年收入预测分别上调8.6%及2.7%，每股盈测则上调29.5%及15.4%，其目标价由25港元上调至28港元。该行表示公司去年收入同比升7.7%至101亿元人民币，纯利同比升26.9%至33亿元人民币。管理层预料，今年创新药品收入贡献增至70%，并目标今年销售达双位数增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094673.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422132354","title":"《大行报告》花旗升翰森制药(03692.HK)目标价至28元  目标今年销售双位数增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2422132354","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422132354?lang=zh_cn&edition=full","pubTime":"2024-03-28 15:38","pubTimestamp":1711611480,"startTime":"0","endTime":"0","summary":"花旗发表报告指，翰森制药(03692.HK) 去年收入按年升7.7%至101亿元人民币，纯利按年升26.9%至33亿元人民币。管理层预料，今年创新药品收入贡献增至70%，并目标今年销售达双位数增长。该行将公司今年和明年收入预测分别上调8.6%及2.7%，每股盈测则上调29.5%及15.4%，其目标价由25元上调至28元，维持其评级为“买入”。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-28 12:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338446/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422901984","title":"《大行报告》中金升翰森制药(03692.HK)目标价27.2%至17.81元  创新药收入占比提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2422901984","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422901984?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:08","pubTimestamp":1711591680,"startTime":"0","endTime":"0","summary":"中金发表报告指，翰森制药去年收入101亿元人民币，按年增长7.7%；净利润32.8亿元人民币，按年增长26.9%，高于该行预期，主因产品对外授权的首付款记账。该行指，关注翰森制药今年创新药进一步放量和早期临床管线数据读出。中金指，由于合作首付款记账部分将于今年确认，加上预期公司三费控制良好，因此上调今年收入和净利润预测各2%和11%至115.66和34.3亿人民币，首次引入明年盈利预测35.6亿元。维持“跑赢行业”评级，上调目标价27.2%至17.81港元。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201021164017612_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201021164017612_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338136/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422904641","title":"南向资金3月27日净买入翰森制药22.80万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2422904641","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422904641?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:31","pubTimestamp":1711589485,"startTime":"0","endTime":"0","summary":"3月27日, 南向资金增持翰森制药22.80万股，连续5日增持。截止当日收盘，港股通共持有翰森制药18262.63万股，占流通股3.07%。翰森制药近5个交易日上涨3.61%，港股通累计增持419.80万股；近20个交易日上涨16.04%，港股通累计增持975.76万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032810184587be5ab4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032810184587be5ab4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422908186","title":"中金：维持翰森制药(03692)“跑赢行业”评级 目标价升至17.81港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422908186","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422908186?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:20","pubTimestamp":1711588823,"startTime":"0","endTime":"0","summary":"中金预计，翰森制药(03692)阿美乐2023年销售额同比增长约12%，24年接近20%同比增长。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240328/20240328092104_68406.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240328/20240328092104_68406.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094369.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422972631","title":"翰森制药(03692.HK)：创新药收入占比提升 ADC管线全球推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2422972631","media":"中金公司","top":-1,"share":"https://www.laohu8.com/m/news/2422972631?lang=zh_cn&edition=full","pubTime":"2024-03-28 07:51","pubTimestamp":1711583513,"startTime":"0","endTime":"0","summary":"发展趋势创新药占比持续提升，早期管线全球合作有效推进。2023 年公司达成多项商业化合作，包括对外授权GSK、引进德琪医药塞利尼索和24 年3 月与普米斯扩大EGFRxcMET 双抗的合作。截至2023 年底，公司账面货币资金储备超过220 亿人民币，是公司研发及BD 方面投入的有力保障。23 年公司7 款获批创新药均已被纳入国家医保目录，公司预计24 年创新药收入占比将达到70%以上。公司预计阿美乐用于NSCLC 辅助治疗临床将在1H24 达到随访事件数，预计2H24 递交上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280822298b6b685b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280822298b6b685b&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1146},{"period":"3month","weight":0.3372},{"period":"6month","weight":0.2968},{"period":"1year","weight":0.1347},{"period":"ytd","weight":0.0368}],"compareEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":0.02},{"period":"3month","weight":0.0584},{"period":"6month","weight":-0.0127},{"period":"1year","weight":-0.1569},{"period":"ytd","weight":-0.0128}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事药品研发、生产及销售业务的中国投资控股公司。该公司的主要产品包括欧兰宁、阿美宁、普来乐、泽菲、昕维、昕美、泽坦、迈灵达、恒捷、恒森、孚来迪和瑞波特等。该公司产品主要用于中枢神经系统疾病、抗肿瘤、抗感染、糖尿病、消化道和心血管治疗。该公司主要在中国内地销售产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.024511},{"month":2,"riseRate":0.4,"avgChangeRate":-0.000669},{"month":3,"riseRate":0.2,"avgChangeRate":-0.042173},{"month":4,"riseRate":0.6,"avgChangeRate":0.027999},{"month":5,"riseRate":0.75,"avgChangeRate":0.030115},{"month":6,"riseRate":0.5,"avgChangeRate":0.041662},{"month":7,"riseRate":0.4,"avgChangeRate":-0.048485},{"month":8,"riseRate":0.6,"avgChangeRate":-0.010974},{"month":9,"riseRate":0.4,"avgChangeRate":-0.05981},{"month":10,"riseRate":0.2,"avgChangeRate":0.031364},{"month":11,"riseRate":0.6,"avgChangeRate":0.050363},{"month":12,"riseRate":0.8,"avgChangeRate":0.06514}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}